IC
ICICI Prudential Healthcare Fund Direct Growth
Latest NAV
+7.97% 1Y
Sign In to Add to Portfolio
Benchmark: BSE Healthcare TRI
Expense ratio
1.31%
AUM
₹6,996 Cr
Min SIP
₹100
Min lump sum
₹5,000
1Y
+7.97%
3Y (ann.)
+21.11%
5Y (ann.)
+15.55%
Launched
Jul 2018
Where the NAV sits & how risky it is
₹45.92
52-week range
at 75%
₹45.92
Low 23 Mar 2026₹39.41
High 11 Aug 2026₹48.12
Risk level
Very High
Low
Very high
NAV history
16 Jul 2018
Since inception
01 Oct 2026
Returns by period
1W
-2.65%
1M
-3.22%
3M
-1.44%
6M
+15.32%
1Y
+7.97%
3Y
+21.11%
5Y
+15.55%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
min SIP ₹100
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. Actual returns vary and are not guaranteed.
Where your money goes
AS OF 31 MAY 2026
Equity 99.82%
Cash & other 10.19%
Sector split
Country split
Top 5 hold 40.3%
Top 10 hold 60.7%
42 equity holdings
Equity holdings
(top 30)
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical
INE044A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
12.09%
|
+4.52% |
| 2 | Dr Reddys Laboratories
INE089A01031 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
7.70%
|
+0.02% |
| 3 | Cipla
INE059A01026 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
7.45%
|
-8.03% |
| 4 | Mankind Pharma
INE634S01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
7.03%
|
+8.18% |
| 5 | Divis Laboratories
INE361B01024 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
6.06%
|
+3.85% |
| 6 | Biocon
INE376G01013 |
Healthcare Biotechnology |
India |
4.71%
|
+5.26% |
| 7 | Cohance Lifesciences
INE03QK01018 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.37%
|
-18.56% |
| 8 | Alkem Laboratories
INE540L01014 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.08%
|
-2.98% |
| 9 | Medplus Health Services
INE804L01022 |
Healthcare Pharmaceutical Retailers |
India |
3.86%
|
+6.46% |
| 10 | Max Healthcare Institute
INE027H01010 |
Healthcare Medical Care Facilities |
India |
3.36%
|
-3.35% |
About this scheme
To generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. However there can be no assurance or guarantee that the investment objectives of the scheme would be achieved.
Fund manager(s): Priyanka Khandelwal, Dharmesh Kakkad
Exit load: Exit load of 1% if redeemed within 15 days.
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
12 Jul 2018
Lump-sum min
₹5,000
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
Nippon India Taiwan Equity Fund Direct Growth
1▲ 113.6 pts ahead of this fund
Franklin Asian Equity Fund Direct Growth
2▲ 25.4 pts ahead of this fund
Nippon India Japan Equity Fund - Direct Plan - Growth Plan - Bonus Option
3▲ 22.6 pts ahead of this fund
Nippon India Japan Equity Fund Direct Growth
4▲ 22.6 pts ahead of this fund
Bank of India Small Cap Fund Direct Growth
5▲ 21.3 pts ahead of this fund
TRUSTMF Small Cap Fund Direct Growth
6▲ 21.2 pts ahead of this fund